Agenus Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026

Company Profile

IndustryBiotechnology

SectorHealthcare

ExchangeNASDAQ

Market Capitalization308.91 mln

Float39.92 mln

Earnings Date11/05/2026

EPS

2.53

Solid

P / E

2.70

Deeply undervalued

Piotroski F-Score

6 / 9

Solid

Beneish M-Score

57.54

Highly suspicious

1-Year Forecast

26.33

Transformational upside

Relative Strength

94 / 100

Top performer

Business Description

Agenus Inc. is a US-based biotechnology company focused on developing treatments that use the body's immune system to fight cancer and infectious diseases. Founded in 1994 and headquartered in Lexington, Massachusetts, the company has built a broad pipeline of experimental drugs, several of which are currently in clinical trials. Agenus works alongside major pharmaceutical partners including Bristol-Myers Squibb, Merck, Gilead Sciences, and Incyte Corporation to advance these treatments toward patients.

Key Fundamentals

EPS2.53

P/E2.70

ROE-38.12

RPS3.64

ROIC13.03

ROA45.77

Interest Cover0.60

EBITDA, mln156

EV / EBITDA3.60

EV / EBIT3.71

Revenue, mln133

EV / Revenue4.23

Quote Details

Last 6.84

Change -0.25 (-3.53%)

Open 6.87

Volume 564,300

Turnover 3,859,812

Average Volume 851,007

Financial Ratios

Pre-Tax Profit Margin69

Current Ratio0.34

Price / Sales1.85

PEG Ratio1.44

Financial Strength

Altman Z-Score-14.31

Piotroski F-Score 6 / 9

Beneish M-Score57.54

1-Year Target Price26.33

Short Ratio6.16

Short % of Float15.69

Price Performance & Relative Strength

Period	Price Performance	Relative Strength
1 Week	8.06%	92 / 100
1 Month	-17.89%	20 / 100
2 Months	11.58%	89 / 100
6 Months	78.13%	98 / 100
1 Year	77.66%	95 / 100